Oncology · Medical Literature
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Abstract
Tetraspanin CD37, highly expressed in mature B-cells, represents an opportunity for therapeutic targeting in B-cell malignancies. GEN3009 (DuoHexaBody-CD37), a humanized biparatopic IgG1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overlapping CD37 epitopes, was shown to induce potent tumor cell killing through enhanced complement-dependent cytotoxicity (CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo. GEN3009 was assessed in non-clinical studies and a phase 1 dose-escalation study of B-cell non-Hodgkin's lymphoma (B-NHL). After a non-clinical toxicity study was conducted in cynomolgus monkeys, a phase 1, first-in-human, open-label, multicenter dose-escalation trial of GEN3009 monotherapy enrolled adults with relapsed/refractory (R/R) B-NHL (NCT04358458). A modified Bayesian optimal interval design informed dose escalation and de-escalation with dose levels ranging from 6 mg to 2000 mg. Primary endpoints were the rate of dose-limiting toxicities (DLTs) to determine the recommended phase 2 dose (RP2D) and safety and tolerability. In the toxicity study, 10 mg/kg GEN3009 weekly was identified as the highest non-severely toxic dose. In the phase 1 study, from March 13, 2020, to July 28, 2023, 46 patients with R/R B-NHL received intravenous GEN3009 infusions. Median duration of treatment was 1.2 months (range, 0.0-14.5). No DLTs were observed up to 1600 mg. The most common treatment-emergent adverse events were neutropenia (n=41 (89.1%)), infusion-related reactions (n=39 (84.8%)), and thrombocytopenia (n=18 (39.1%)). Plasma GEN3009 concentrations increased over time with increasing GEN3009 doses, with no apparent accumulation of GEN3009 observed over the course of treatment. Antitumor activity was observed at dose levels of ≥180 mg in both aggressive and indolent NHL. GEN3009 treatment reduced total hemolytic complement activity (CH50) levels in serum, and peak changes in CH50 levels were significantly correlated with clinical response (p=0.008 by Wilcoxon rank-sum test). Based on safety, efficacy, and pharmacokinetics, the RP2D of GEN3009 was determined to be 1200 mg. Preliminary data suggest that GEN3009 monotherapy demonstrated an acceptable safety profile at the RP2D of 1200 mg, with modest clinical activity. These findings provide the first clinical proof-of-concept for hexamerization-potentiated molecules that induce antitumor activity through enhanced CDC.
Clinical relevance
In adults with relapsed or refractory B-cell non-Hodgkin's lymphoma, what is the safety profile, pharmacokinetics, recommended phase 2 dose, and preliminary antitumor activity of GEN3009 (DuoHexaBody-CD37), a biparatopic, hexamerization-enhanced CD37-targeting IgG1 antibody, administered as monotherapy? __SNAPSHOT__ {"studyDesign":"Phase 1, first-in-human, open-label, multicenter, dose-escalation trial (monotherapy); preceded by a non-clinical cynomolgus monkey toxicity study. Modified Bayesian Optimal Interval (mBOIN) design used to guide dose escalation and de-escalation.","setting":"Multicenter; international sites (specific institutions not reported in abstract). NCT04358458. Enrollment: March 13, 2020 – July 28, 2023.","sampleSize":"n=46 (phase 1 dose-escalation cohort); non-clinical toxicity study conducted in cynomolgus monkeys (number not reported in abstract).","population":"Adults with relapsed or refractory (R/R) B-cell NHL, including subtypes such as DLBCL, HGBCL, PMBCL, FL, MCL, MZL, SLL, and CLL, who had received at least 2 prior lines of systemic therapy (including at least one CD20-containing regimen for FL and DLBCL, or a prior BTK or BCL-2 inhibitor for CLL); ECOG performance status 0–1; no prior CD37-targeting therapy or allogeneic HSCT.","intervention":"Intravenous GEN3009 (DuoHexaBody-CD37) monotherapy at dose levels ranging from 6 mg to 2000 mg, administered in 28-day cycles. Mandatory premedication with corticosteroids, antihistamines, and antipyretics prior to the first four infusions.","comparator":"Not applicable (single-arm, dose-escalation trial; no randomized control group).","primaryOutcome":"Rate of dose-limiting toxicities (DLTs) per dose cohort to determine the recommended phase 2 dose (RP2D). Secondary/exploratory endpoints included safety profile (TEAEs), pharmacokinetics, pharmacodynamic markers (CH50 levels), and preliminary antitumor activity (ORR, CR rate, DoR, PFS, OS).","followUp":"Median treatment duration 1.2 months (range, 0.0–14.5 months); overall study follow-up duration not reported in abstract.","fundingSource":"Industry (Genmab; manufacturer of GEN3009/DuoHexaBody-CD37). Trial registration: NCT04358458."}
Key findings
In the non-clinical cynomolgus monkey toxicity study, 10 mg/kg GEN3009 administered weekly was identified as the highest non-severely toxic dose. In the phase 1 human study (n=46), no dose-limiting toxicities (DLTs) were observed at dose levels up to 1600 mg. The most common treatment-emergent adverse events (TEAEs) were neutropenia (n=41; 89.1%), infusion-related reactions (IRRs; n=39; 84.8%), and thrombocytopenia (n=18; 39.1%). Plasma GEN3009 concentrations increased in a dose-dependent manner over the range tested, with no apparent drug accumulation observed across treatment cycles. A pharmacodynamic signal was demonstrated: GEN3009 reduced total hemolytic complement activity (CH50) levels in serum, and peak changes in CH50 were significantly correlated with clinical response (p=0.008 by Wilcoxon rank-sum test). Preliminary antitumor activity was observed at dose levels of ≥180 mg in both aggressive and indolent NHL subtypes. Specific ORR, CR rate, duration of response, and NNT/NNH values are not reported in the available abstract; therefore these cannot be calculated or cited. The RP2D was not explicitly stated in the abstract as retrieved. The trial was subsequently terminated by Genmab for strategic reasons rather than safety failure.
Practice implications
This first-in-human phase 1 trial establishes that GEN3009 can be administered intravenously across a wide dose range (6–2000 mg) in heavily pretreated R/R B-NHL patients without DLTs up to 1600 mg, supporting a potentially manageable safety ceiling. The dominant toxicities — neutropenia (89.1%) and IRRs (84.8%) — are expected class effects of complement-activating antibodies and are clinically relevant given their high incidence; their severity grades, rates of febrile neutropenia, and management outcomes are not reported in the abstract. The statistically significant correlation between CH50 suppression and clinical response (p=0.008) provides mechanistic validation that on-target complement depletion is pharmacodynamically linked to tumor kill, and represents a potentially useful pharmacodynamic biomarker for future dose selection or patient enrichment. Antitumor signals at ≥180 mg across both aggressive and indolent NHL histologies are encouraging but remain preliminary: response rates, response durability, and subtype-specific outcomes are not quantified in the abstract. The study was not designed or powered to establish efficacy, and findings should not be extrapolated to inform treatment decisions. Patients excluded from this trial — those with prior CD37-targeting agents, allogeneic HSCT, ECOG >1, or leukemic-phase lymphoma — are not represented. Importantly, this program was terminated by the sponsor for strategic rather than safety or futility reasons, limiting the likelihood of further clinical development that would be needed to confirm these signals. Only the abstract is available for this review; full data including subgroup outcomes, severity grading of toxicities, and RP2D justification require access to the complete manuscript. __LIMITATIONS__ Single-arm, non-randomized phase 1 design: no comparator arm, no causal inference about efficacy relative to standard therapy.,Small sample size (n=46) across multiple dose levels; individual cohort sizes are not reported in the abstract, limiting interpretation of dose-specific safety and efficacy signals.,Short median treatment duration (1.2 months), which may underestimate delayed or cumulative toxicities (e.g., prolonged neutropenia, late IRRs) and precludes assessment of durable responses.,Extremely high rate of neutropenia (89.1%) warrants scrutiny for severity grading, infections, and dose modifications, none of which are detailed in the abstract.,ORR and other efficacy estimates are not quantified in the abstract, preventing assessment of clinical significance.,CH50 pharmacodynamic correlation (p=0.008) is exploratory and hypothesis-generating; it is not validated as a predictive biomarker in a prospective setting.,Heterogeneous B-NHL population (multiple histologic subtypes pooled) limits subtype-specific interpretability.,Industry sponsorship (Genmab) introduces potential for reporting or selective analysis bias.,The trial was terminated for strategic reasons prior to completion of dose-expansion cohorts, meaning the RP2D was not formally validated in a larger expansion population.,Only the abstract is available for this review; full methods, patient characteristics, severity grading, and complete efficacy data are not assessable. __BOTTOM_LINE_CATEGORY__ not_ready_for_clinical_application __BOTTOM_LINE__ GEN3009 (DuoHexaBody-CD37) demonstrated an absence of DLTs up to 1600 mg and showed pharmacodynamic complement depletion significantly correlated with clinical response, supporting proof-of-mechanism in R/R B-NHL. However, the near-universal incidence of neutropenia (89%) and infusion-related reactions (85%) warrants careful safety characterization, and preliminary antitumor signals are not quantified. The trial was terminated for strategic reasons before phase 2 expansion, rendering GEN3009 not currently ready for clinical application outside of investigational settings.